Exelixis (EXEL) Stock Price, Quote, News & History | Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,821.08+0.31%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Exelixis Inc (EXEL) Stock Price, Quote, News & History

EXELNASDAQ

Trade with Public

Trade with Public

$59.86

0.841.42%

Last update: Oct 9, 4:00 PM

$59.35

0.330.55%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$59.00

Close

$59.86

Volume / Avg.

2.56M / 2.33M

Day Range

$59.86 - $59.88

52 Wk Range

33.76 - 61.14

Market Cap

$14.99B

P/E Ratio

18.56

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

15.03%

Days to Cover

12.65

Recent Exelixis Inc News

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.

Vandana Singh

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratings page for complete view.

Avi Kapoor

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.

Vandana Singh

Prologis To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page.

Avi Kapoor

Why Is Merck Stock Falling Tuesday?

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.18B

Investing Cash Flow (TTM)

93.01M

Financing Cash Flow (TTM)

-1.16B

Free Cash Flow (TTM)

1.16B

Capital Expenditure (TTM)

-25.24M

Net Change in Cash (TTM)

117.02M

Analyst Trends and Forecast

0

0

0

0

Jun

1

4

Jul

1

Aug

0

0

0

0

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$14.16B

PE Ratio (TTM)

18.56

PE Ratio (FWD)

13.76

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.55

PB Ratio (TTM)

7.93

Earnings Yield % (TTM)

5.39%

Earnings Yield % (FWD)

7.27%

EV / EBITDA (TTM)

13.67

Price / EBITDA (TTM)

15.65

Price / Free Cash Flow (TTM)

13.78

Book Value / Share

$7.44

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$281.45M

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-